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Introduction:  Perampanel  is  a selective,  noncompetitive  AMPA  receptor  antagonist  approved  as  adjunctive
treatment  for  partial  seizures.  To assess  potential  for delayed  cardiac  repolarization,  a Phase  I thorough
QT  study  was  performed,  supplemented  by  plasma  concentration–QT  data  modeled  from  3  pooled  Phase
III  studies.
Methods:  The  Phase  I thorough  QT study  (double-blind,  combined  ﬁxed-sequence,  parallel-group)  quan-
tiﬁed  the  effect  of perampanel  (6 mg once  daily  for  7  days,  followed  by  dose  escalation  to a single  8-mg
dose,  a single  10-mg  dose,  then  12 mg  once  daily  for 7 days),  moxiﬂoxacin  positive  control  (single  400-mg
dose  on Day  16),  and  placebo  on QT  interval  duration  in  healthy  subjects  (N =  261).  Electrocardiograms
were recorded  at baseline,  Day  7 (post  6 mg dose),  and  Day  16  (post  12  mg dose).  Statistical  comparisons
were  between  the highest  approved  perampanel  dose  (12  mg)  versus  placebo,  a  “mid-therapeutic”  dose
(6 mg)  versus  placebo,  and  moxiﬂoxacin  versus  placebo.  Acknowledging  that  the Phase  I  thorough  QT
study  could  not  incorporate  a  true  “supratherapeutic”  dose  due  to  length  of  titration  and  tolerability  con-
cerns  in healthy  subjects,  Phase  III studies  of  perampanel  included  expanded  electrocardiogram  safety
evaluations  speciﬁcally  intended  to support  concentration–QT  response  modeling.  The lack  of  effect  of
perampanel  on  the  QT  interval  is shown  from  pooled  analysis  of  3  double-blind,  placebo-controlled,  19-
week,  Phase  III  studies  with  perampanel  doses  ≤12 mg  (N =  1038,  total  perampanel;  and  N  = 442, placebo)
in  patients  with  partial  seizures.  QT measures  were  corrected  for heart  rate  using  Fridericia’s  (QTcF;  the
primary  endpoint)  and  Bazett’s  (QTcB)  formulas.
Results: In the Phase  I thorough  QT  study,  the positive  control  moxiﬂoxacin  caused  peak  time-matched,
baseline-adjusted,  placebo-corrected  ()  QTcF  of  12.15  ms at 4 h postdose,  conﬁrming  a  drug  effect
on QTc  interval  and  study  assessment  sensitivity.  Mean  baseline-adjusted  ()  QTcF  versus  nominal  time
curves  were  comparable  between  perampanel  12  mg  and  placebo,  with  most  QTcF  values  being slightly
negative. Healthy  subjects  receiving  perampanel  6 and  12  mg doses  for 7 days  showed  no  evidence  of
effects  on cardiac  repolarization.  Peak  QTcF  was  2.34  ms  at 1.5 h  postdose  for  perampanel  6  mg  and
3.92  ms at  0.5  h postdose  for  perampanel  12 mg.  At every  time  point,  the  upper 95%  conﬁdence  limit
of  QTcF  for  perampanel  6 and  12  mg was  <10  ms.  Phase  III studies  revealed  no  clinically  signiﬁcant
Abbreviations: AE, adverse event; AED, antiepileptic drug; ANOVA, analysis of variance; AUC, area under the concentration–time curve; BMI, body mass index; CI,
onﬁdence interval; Cmax, maximum plasma concentration; ECG, electrocardiogram; hERG, human ether-à-go-go-related gene; IC50, 50% inhibitory concentration; ICH,
nternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; MTD, maximum tolerated dose; QTcB, Bazett’s
ormula for QT interval corrected for heart rate; QTcF, Fridericia’s formula for QT interval corrected for heart rate; QTci, individual formula for QT interval corrected for heart
ate;  SUDEP, sudden unexpected death in epilepsy; TdP, torsade de pointes; tmax, time to maximum plasma concentration relative to time of dosing.
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difference  between  patients  with  partial  seizures  treated  with  perampanel  or placebo  in  QTcF  and  QTcB
values  >450  ms,  with  no  dose-dependent  increases  or large  incremental  changes  from  baseline  of >60  ms.
Regression  analysis  of individual  plasma  perampanel  concentrations  versus  corresponding  QTc  interval
values  in  Phase  I thorough  QT and  Phase  III studies  demonstrated  no relationship  between  perampanel
concentrations  and  QT interval  duration.
Conclusion:  Treatment  with  perampanel  6 mg  and  12  mg  for 7 days  did  not  delay  cardiac  repolarization  in
healthy  volunteers.  In a population  analysis  of  1480  patients  with  partial  seizures  treated  with  perampanel
doses ≤12  mg or placebo,  no clinically  signiﬁcant  trends  in QT interval  data  were  noted.  Based  on the
thorough  QT  study  and evaluations  from  pooled  Phase  III studies,  there  is no  evidence  of  prolonged  QT
interval  duration  with  perampanel  treatment.
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The QT interval is the duration of ventricular depolarization
nd subsequent repolarization as measured on an electrocardio-
ram (ECG) from the beginning of the QRS complex to the end
f the T wave (ICH Expert Working Group, 2005). Prolongation
f the QT interval has been identiﬁed as a potential risk for car-
iac arrhythmias, most commonly torsade de pointes (TdP), during
reatment with a variety of drugs (ICH Expert Working Group,
005; Pollard et al., 2008; Redfern et al., 2003). Delayed repolar-
zation results from suppression of potassium current in cardiac
issues, the rapidly activating delayed rectiﬁer that is mediated by
he human ether-à-go-go-related gene (hERG)-encoded voltage-
ependent potassium channel (hERG K+ channel) (Pollard et al.,
008; Redfern et al., 2003). Regulatory authorities require most
linical programs to examine the potential for drug-induced QT
nterval prolongation by conducting a thorough QT study during
he course of drug development.
Perampanel is a selective, orally active, noncompetitive AMPA
eceptor antagonist approved in both Europe and the United
tates for adjunctive treatment of partial seizures with or with-
ut secondarily generalized seizures in patients 12 years of
ge or older with epilepsy, and in Canada for adult patients
8 years of age or; older with epilepsy (Fycompa Summary of
roduct Characteristcs, 2012; Fycompa Product Monogrpah, 2013;
ycompa Prescribing Information, 2014). Perampanel has demon-
trated efﬁcacy and tolerability in partial seizures in patients ≥12
ears of age in 3 multicenter, double-blind, randomized, placebo-
ontrolled Phase III studies (French et al., 2012, 2013; Krauss et al.,
012).
In vitro studies indicate that perampanel blocks the hERG K+
hannel in cultured cells in a dose-dependent manner at con-
entrations ≥10 mol/L (≥3629 ng/mL), with an estimated 50%
nhibitory concentration (IC50) of 15.8 mol/L (5733.82 ng/mL). No
igniﬁcant inhibition was observed at concentrations of ≤3 mol/L.
n clinical studies, the highest plasma perampanel concentra-
ion observed in healthy subjects and patients with epilepsy
as approximately 2500 ng/mL, corresponding to a free drug
oncentration of 0.34 mol/L. This equates to an approximate 45-
old margin between the hERG IC50 and the plasma free drug
oncentration; published literature suggests that drugs with a
30-fold safety margin are typically not associated with TdP, for
hich QT interval prolongation is a risk (Pollard et al., 2008;
edfern et al., 2003). Thus, therapeutic doses of perampanel
ere anticipated to have a low arrhythmogenic or TdP poten-
ial.
This report examines a Phase I thorough QT study of the effect of
erampanel on QT interval duration and the relationship between
lasma perampanel concentrations and QT interval duration in
ealthy subjects. The International Conference on Harmonisation
ICH) E14 Guidance, The Clinical Evaluation of QT/QTc Interval Pro-
ongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs,hed  by  Elsevier  B.V. This is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
provides speciﬁc recommendations concerning the design, con-
duct, analysis, and interpretation of clinical studies to assess the
potential of a drug to delay cardiac repolarization (ICH Expert
Working Group, 2005). However, due to safety and tolerability con-
cerns in healthy subjects, the Phase I thorough QT study could not
include the recommended multiple dosing regimen of perampanel
at the maximum therapeutic exposure (ICH Expert Working Group,
2005). Acknowledging that the Phase I thorough QT study could not
incorporate a true ‘supratherapeutic’ dose of perampanel due to the
short duration of titration and tolerability concerns in healthy sub-
jects, this report includes plasma concentration–QT data (obtained
from expanded ECG safety evaluations) modeled from 3 pooled
Phase III studies.
Materials and methods
Standard protocol approvals, registration, and patient consents
This analysis consists of a Phase I thorough QT  study of the
effect of perampanel treatment on QT interval duration (E2007-
A001-013) conducted between September 2007 and March 2008
at a single site in the United States and is supplemented by plasma
concentration–QT data modeled from 3 pooled Phase III studies
(Study 304, NCT00699972; Study 305, NCT00699582; and Study
306, NCT00700310) conducted between April 2008 and January
2011 in more than 40 countries (French et al., 2012, 2013; Krauss
et al., 2012). All studies were conducted in accordance with the Dec-
laration of Helsinki, European Medicines Agency requirements, and
the US Code of Federal Regulations, as appropriate. Study protocols,
amendments, and informed consents were reviewed by national
regulatory authorities in each country and by independent ethics
committees or institutional review boards for each site. Prior to par-
ticipation, all patients provided written informed consent (French
et al., 2012, 2013; Krauss et al., 2012).
Patients
Eligible subjects for the Phase I thorough QT study included
healthy male and female subjects 18–55 years of age, with a body
mass index (BMI) of 18–32 kg/m2. Of note, subjects who had evi-
dence of any clinically signiﬁcant disease or abnormality (including
hepatic impairment), or who had a clinically signiﬁcant illness dur-
ing the 2 months leading up to the start of study drug treatment,
were excluded. The concomitant medications taken by subjects
were also recorded.
Eligible patients for the three Phase III studies included indi-
viduals ≥12 years of age diagnosed with partial seizures with orInternational League Against Epilepsy Classiﬁcation of Epileptic
Seizures (ILAE, 1981) who had experienced ≥2 antiepileptic drug
(AED) failures and had ≥5 partial seizures during baseline. Patients
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ad to have been on stable doses of up to 3 approved AEDs prior
o randomization (French et al., 2012, 2013; Krauss et al., 2012).
oncomitant medications taken by patients were recorded. Inclu-
ion and exclusion criteria were similar for the Phase III studies and
ave been published previously.
rial designs
The Phase I thorough QT study had a double-blind, active-
nd placebo-controlled, combined ﬁxed-sequence, parallel-group
esign and included 3 treatment arms: perampanel, placebo,
nd moxiﬂoxacin. Subjects were treated for 16 days. Because
oxiﬂoxacin treatment affects cardiac repolarization and it can
herefore be used to demonstrate assay sensitivity, it was chosen
s a positive control (Bloomﬁeld et al., 2008). The perampanel arm
ncluded once-daily treatment with perampanel 6 mg  for 7 days
Days 1–7), followed by a dose escalation (a single 8-mg dose on Day
 and a single 10-mg dose on Day 9), and then once-daily treatment
ith perampanel 12 mg  for 7 days (Days 10–16); on Day 16, sub-
ects were administered a single placebo capsule for moxiﬂoxacin.
ubjects in the placebo arm were administered the placebo tablet
or perampanel on Days 1–16, followed by the placebo capsule for
oxiﬂoxacin on Day 16. Subjects in the moxiﬂoxacin arm were
dministered perampanel placebo for Days 1–16, followed by a
ingle dose of 400 mg  moxiﬂoxacin on Day 16 (Fig. 1). Study drug
osing was in the evening after a meal, with the exception of the
n-treatment QT assessment days (Days 7 and 16), when the study
rug was administered in the morning, under fasted conditions.
The Phase III studies included a 6-week baseline, prerandom-
zation period, after which patients were randomized to once-daily
ouble-blind treatment with perampanel or placebo for 19 weeks
6-week titration, 13-week maintenance), and then a 4-week
ollow-up (Fig. 2) (French et al., 2012, 2013; Krauss et al., 2012).
T assessment and pharmacokinetic sampling
To quantify the effect of perampanel on QT interval duration in
he Phase I thorough QT study, a QT assessment was conducted
t baseline (Day −1) and on Days 7 (post 6 mg  dose) and 16
post 12 mg  dose) of treatment. The QT assessment consisted of a
erial 12-lead ECG (3 standard ECGs per time point, approximately
 min  apart). To explore the relationship between plasma concen-
ration of perampanel and QT interval duration, pharmacokinetic
ampling was conducted on Days 7 and 16. ECG measurements
ere taken immediately prior to pharmacokinetic sampling. The
aseline QT assessment was time-matched to the treatment QT
ssessments, and subjects received identical meals and observed
dentical food/fast schedules on the days of QT assessment.
In the Phase III studies, ECGs were conducted at baseline (Week
6), at Weeks 0 and 6 during the titration period, at Weeks 14 and
9 during the maintenance period, and at the end of the follow-up
Week 23). Blood samples for the measurement of plasma peram-
anel concentration were collected at Weeks 10, 14, and 19 during
he maintenance period and at the end of the follow-up (Week 23)
Fig. 2).
tatistical analysis
Analysis of QT interval duration in the Phase I thorough QT
tudy employed Fridericia’s method of correction for heart rate
QTcF) derived from ECGs taken at baseline (Day −1) and Days 7
nd 16. Statistical comparisons were made between perampanel
2 mg  and placebo, perampanel 6 mg  and placebo, and moxi-
oxacin and placebo. Correction for heart rate was also made using
azett’s and individual correction formulas (QTcB and QTci, respec-
ively). The mean differences at each time point in change fromch 114 (2015) 122–130
baseline between active treatment and placebo were compared
using a repeated measures mixed effects analysis of variance
(ANOVA). The mean time-matched, baseline-corrected difference is
presented, along with a one-sided 95% upper conﬁdence bound on
the difference. An upper conﬁdence limit <10 ms indicates that the
active treatment did not cause a clinically relevant increase in the
QT interval. In the moxiﬂoxacin arm, assay sensitivity was tested
using point estimates and conﬁdence intervals (CIs) (two-sided 95%
CI) from an ANOVA model at each time point. A signiﬁcant p value
with a >5 ms  difference indicated assay sensitivity.
Pharmacokinetic parameters were derived from observed
plasma concentrations by standard non-compartmental methods.
Parameters of interest included maximum plasma concentration
(Cmax), time to maximum plasma concentration relative to time of
dosing (tmax), and area under the concentration–time curve from
predose to 12 h postdose (AUC0–12).
Results
Phase I thorough QT study of the effect of perampanel treatment
on QT interval duration
Subject disposition and demographics
Two hundred sixty-one subjects were randomized for treat-
ment (perampanel, N = 111; placebo, N = 75; moxiﬂoxacin, N = 75).
Two hundred ﬁfty subjects completed the Day 7 assessment and
233 subjects completed the Day 16 assessment. Twenty-four sub-
jects (21.6%) in the perampanel treatment group withdrew from
the study, primarily due to adverse events (AEs) (12.6%). The most
commonly reported AEs were dizziness, headache, dysarthria, som-
nolence, ataxia, and positive rombergism. Four subjects (5.3%) in
the moxiﬂoxacin group discontinued, mainly as a result of abnor-
mal  laboratory values (2.7%). No subjects in the placebo group
withdrew from the study (Table 1). The use of concomitant med-
ications was  recorded in 39 subjects; 13 (12.1%) perampanel-,
12 (16.0%) placebo-, and 14 (18.7%) moxiﬂoxacin-treated subjects
received counteractive treatment for adverse events. Based on the
type of medications and when they were taken, it is unlikely that
the concomitant medications interfered with pharmacokinetic and
pharmacodynamic assessments.
Demographics and baseline characteristics, including age, sex,
race, body weight, height, and BMI, were similar across all 3 treat-
ment arms (Table 2).
Moxiﬂoxacin treatment affects cardiac repolarization and
demonstrates assay sensitivity
Following treatment with placebo, there was  a slight decrease
in QTcF at 0.5 h, which then returned to baseline and stayed at
a relatively constant QTcF level of 0 ms  thereafter on Days 7 and
16 (Fig. 3). In contrast, a steep increase in QTcF from −0.75 to
7.10 ms  was  observed between 0.5 and 1.0 h postdose following
treatment with a single administration of moxiﬂoxacin 400 mg  on
Day 16 (Fig. 3B). From 1.0 to 4.0 h the QTcF was maintained at
approximately 10.00–11.50 ms, and then declined and remained
at a stable 6.00–7.00 ms  range between 6.0 and 12.0 h. A time-
matched, baseline-adjusted analysis of the mean QTcF difference
(QTcF) between moxiﬂoxacin and placebo indicated a QTcF
>5 ms  at every time point between 1.0 and 12.0 h postdose; further-
more, moxiﬂoxacin treatment resulted in a peak QTcF effect of
12.15 ms at 4 h (data not shown). Overall, QTc differences follow-
ing moxiﬂoxacin treatment compared with placebo indicate assay
sensitivity (Bloomﬁeld et al., 2008).Perampanel treatment does not affect cardiac repolarization
Perampanel did not have an effect on heart rate (data
not shown). At the 6 mg  “mid-therapeutic” and the 12 mg
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Figure 1. Design of the Phase I thorough QT study in healthy subjects. *QT assessment conducted, followed by blood sample collection. Mox  = moxiﬂoxacin; PBO = placebo;
PER  = perampanel.
Figure 2. Design of the Phase III studies to evaluate perampanel treatment in patients with partial seizures. *ECG (electrocardiogram) assessment conducted; †Blood samples
collected for perampanel concentration.
Table 1
Summary of subject disposition in the Phase I thorough QT study (all subjects).
Category Number (%) of subjects
Placebo
N = 75
Perampanel
N = 111a
Moxiﬂoxacin
N = 75
Completed Day 7 assessment 75 (100) 101 (91.0) 74 (98.7)
Completed Day 16 assessment 75 (100) 87 (78.4) 71 (94.7)
Number discontinued 0 24 (21.6) 4 (5.3)
Reason for discontinuation
Adverse events 0 14 (12.6) 1 (1.3)
Patient withdrew consent 0 7 (6.3) 1 (1.3)
Abnormal laboratory valueb 0 1 (0.9) 2 (2.7)
Otherc 0 2 (1.8) 0
a Three subjects in the perampanel group withdrew consent and 1 subject failed electrocardiogram (ECG) entrance criteria prior to dosing. These 4 subjects were randomized
but  not dosed.
b Two subjects (n = 1 each for perampanel and moxiﬂoxacin groups) discontinued due to abnormal laboratory values, which were also reported as adverse events. One
s  of po
t
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Bubject  in the moxiﬂoxacin group discontinued due to abnormal laboratory value
aking  placebo when discontinued from the study.
c Includes 1 subject who  discontinued due to the ECG requirement and 1 subjecthigh-therapeutic” doses, mean (±SD) QTcF versus nominal time
urves were comparable between the perampanel and placebo
roups, and most QTcF values in both treatment groups were neg-
tive. Time-matched, baseline-adjusted analysis of the mean QTcF
able 2
atient demographics and baseline characteristics in the Phase I thorough QT study (safe
Characteristic Statistic Placebo
N = 75
Age, years Mean (SD) 28.4 (10.
Min,  max  18, 55 
Sex,  n (%) Male 38 (50.7)
Female 37 (49.3)
Race,  n (%) Caucasian 64 (85.3)
Black  2 (2.7) 
Asian  2 (2.7) 
Other 7 (9.3) 
Body  weight, kg Mean (SD) 72.5 (13.
Min,  max  49.5, 105
Height, cm Mean (SD) 171.06 (8
Min, max  154.9, 18
BMI,  kg/m2 Mean (SD) 24.66 (3.
Min,  max  18.2, 31.6
MI = body mass index; SD = standard deviation.sitive pregnancy test. The 2 subjects randomized to the moxiﬂoxacin group were
iscontinued due to noncompliance.difference between perampanel treatment and placebo indicated
that at both doses, perampanel treatment did not have an effect on
QT interval duration in healthy subjects. The peak QTcF was
2.34 ms  at 1.5 h postdose following treatment with perampanel
ty population).
Perampanel
N = 107
Moxiﬂoxacin
N = 75
06) 29.0 (10.68) 29.0 (10.06)
18, 55 18, 54
 53 (49.5) 38 (50.7)
 54 (50.5) 37 (49.3)
 95 (88.8) 60 (80.0)
5 (4.7) 6 (8.0)
1 (0.9) 2 (2.7)
6 (5.6) 7 (9.3)
19) 76.8 (12.68) 74.6 (12.55)
.3 51.8, 110.8 49.5, 100.8
.58) 171.15 (9.83) 170.36 (9.00)
5.4 144.8, 195.6 147.3, 190.5
49) 26.17 (3.26) 25.61 (3.18)
 18.0, 32.0 20.0, 32.2
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Figure 3. Perampanel treatment does not change QTcF from baseline. Data presented as mean change ± standard deviation from baseline following treatment with (A)
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gerampanel 6 mg  and placebo on Day 7 and (B) perampanel 12 mg,  placebo, and mo
 mg,  and 3.92 ms  at 0.5 h postdose following treatment with per-
mpanel 12 mg  (Table 3). At every time point following treatment
ith perampanel 6 mg  or 12 mg,  the upper 95% conﬁdence limit
as <10 ms,  thereby establishing a negative thorough QTc result
nd indicating that perampanel treatment did not cause a clin-
cally relevant prolongation of the QT interval. Similar results
ere observed when using QTcB and QTci correction formulas.
n Day −1 (treatment-free baseline), the number of incidents
f QTcF >450 ms  was comparable among the treatment groups
n = 2, placebo; n = 1, moxiﬂoxacin; n = 1, perampanel). On Day 7,
here was 1 incident of QTcF >450 ms  (4-h postdose) for the per-
mpanel treatment group and no incidents for the placebo and
oxiﬂoxacin groups. On Day 16, there was 1 incident (1-h post-
ose) for the perampanel treatment group, while no subject from
he placebo group reported an incident. As expected from the QT
rolonging nature of moxiﬂoxacin, a total of 10 incidents from 1 h
p to 4 h postdose were reported for the moxiﬂoxacin treatment
roup; no incidents were reported from 6 to 12 h postdose. Noneacin 400 mg on Day 16.
of the subjects from the Phase I study had absolute QTcF >480 ms.
Consistent with this analysis, no relationship was found between
plasma perampanel concentration and QTcF (Fig. 4), as indicated by
the overlapping QTcF range in the perampanel 6 mg,  perampanel
12 mg,  and placebo groups.
An investigation of time-matched, baseline-adjusted analysis of
several ECG parameters (RR, PR, QRS, and QT) between perampanel
6 mg  versus placebo and perampanel 12 mg  versus placebo indi-
cated some small but statistically signiﬁcant differences (p < 0.05).
Signiﬁcant least square (LS) means differences from placebo were
observed in RR (ranging from 34.2 to 41.2 for 6 mg or 12 mg); in PR
(3.6 for 6 mg  only); and in QT (6.2–7.4 for 6 mg or 12 mg)  at various
time points. However, no systematic changes in these parameters
were observed and the statistical outcome was  considered to reﬂect
the large number of comparisons made and the high statistical
power of the study to detect small treatment differences. Overall,
perampanel treatment was not associated with clinically relevant
changes in QT interval, heart rate, or other ECG parameters.
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Table  3
Time-matched, baseline-adjusted QTcF (ms): “mid-therapeutic” (6 mg)  and “high-therapeutic” (12 mg)  dose levels compared to placebo (per-protocol population).
Time point (h) LS mean Difference (QTcF) Upper 95% CLa
Placebo
N = 59
Perampanel
6 mg
N = 79
−0.5 −4.73 −3.25 1.48 3.78
0.5 −6.53 −4.65 1.88 5.07
1.0  −4.46 −3.12 1.34 4.49
1.5  −3.60 −1.26 2.34 5.24
2.0  −3.12 −2.42 0.70 3.80
3.0  −3.08 −3.10 −0.02 2.95
4.0  −0.55 1.67 2.23 4.98
6.0 −3.30 −2.47 0.83 3.40
8.0 −2.56 −0.76 1.80 4.26
12.0  −1.78 −0.68 1.09 3.59
Time  point (h) LS mean Difference (QTcF) Upper 95% CLa
Placebo
N = 59
Perampanel
12 mg
N = 69
−0.5 −2.16 0.28 2.44 5.58
0.5 −5.70 −1.78 3.92 7.48
1.0  −3.95 −1.75 2.20 5.43
1.5  −2.36 −0.71 1.66 4.79
2.0  −1.63 −1.71 −0.08 3.43
3.0  −0.90 −2.64 −1.74 1.20
4.0 −0.68 1.05 1.72 4.80
6.0  −3.10 −1.79 1.31 4.21
8.0  −2.18 −1.21 0.96 3.80
12.0  −2.39 −0.59 1.80 4.49
A QT
t
P
S
i
A
F
fa One-sided 95% conﬁdence limit from an ANOVA model.
NOVA = analysis of variance; CL = conﬁdence limit; LS mean = least squares mean; 
ion  formula).
ooled data from Phase III studiesubject disposition
Pooled data from the Phase III studies included 1480 patients
n the safety population (perampanel, N = 1038; placebo, N = 442).
ll subjects were on a stable dose of at least 1 concomitant AED
igure 4. Perampanel plasma concentrations versus QTcF from the Phase I thorough QT stu
or  heart rate.cF = time-matched, baseline-adjusted, placebo-corrected QTcF (Fridericia’s correc-
during treatment. The most common AEDs, i.e., those taken by at
least 10% of the subjects in any group, were carbamazepine, val-
proic acid, lamotrigine, levetiracetam, topiramate, oxcarbazepine,
clobazam, and clonazepam. Concomitant non-AED medications
were also reported and were similar between perampanel and
placebo-treated subjects (63.2% versus 69.2%, respectively). The
dy in healthy subjects. msec = milliseconds; QTcF = Fridericia’s method of correction
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Table 4
Summary of abnormal QTc results during treatment in the pooled Phase III studies (safety analysis set).
Parameter Placeboa
(N = 442)
n (%)
Perampanela,b
2 mg/day
(N = 180)
n (%)
4 mg/day
(N = 172)
n (%)
8 mg/day
(N = 431)
n (%)
12 mg/day
(N = 255)
n (%)
Total
(N = 1038)
n (%)
Maximum QTcB category
n 428 176 169 419 245 1009
Normal (<430 ms)  333 (77.8) 137 (77.8) 126 (74.6) 315 (75.2) 190 (77.6) 768 (76.1)
Borderline (430–450 ms)  89 (20.8) 39 (22.2) 40 (23.7) 95 (22.7) 545 (22.6) 228 (22.6)
Abnormal (>450 ms) 6  (1.4) 0 3 (1.8) 9 (2.1) 1 (0.4) 13 (1.3)
Highly  abnormal (>500 ms) 0 0 0 0 0 0
Maximum QTcB increment from baseline
n  428 176 169 419 245 1009
Increment of <30 ms from baseline 390 (91.1) 158 (89.8) 152 (89.9) 382 (91.2) 220 (89.8) 912 (90.4)
Increment of 30–60 ms  from baseline 37 (8.6) 18 (10.2) 17 (10.1) 36 (8.6) 24 (9.8) 95 (9.4)
Increment of >60 ms from baseline 1 (0.2) 0 0 1 (0.2) 1 (0.4) 2 (0.2)
Maximum QTcF category
n 428 176 169 419 245 1009
Normal (<430 ms)  392 (91.6) 168 (95.5) 159 (94.1) 385 (91.9) 225 (91.8) 937 (92.9)
Borderline (430–450 ms) 34  (7.9) 7 (4.0) 9 (5.3) 29 (6.9) 19 (7.8) 64 (6.3)
Abnormal (>450 ms)  2 (0.5) 1 (0.6) 1 (0.6) 5 (1.2) 1 (0.4) 8 (0.8)
Highly  abnormal (>500 ms) 0 0 0 0 0 0
Maximum QTcF increment from baseline
n  428 176 169 419 245 1009
Increment of <30 ms from baseline 412 (96.3) 172 (97.7) 165 (97.6) 403 (96.2) 230 (93.9) 970 (96.1)
Increment of 30–60 ms  from baseline 14 (3.3) 4 (2.3) 3 (1.8) 15 (3.6) 15 (6.1) 37 (3.7)
Increment of >60 ms from baseline 2 (0.5) 0 1 (0.6) 1 (0.2) 0 2 (0.2)
Subjects are counted in each applicable category. Percentages are based on the number of subjects in the safety analysis set per treatment group with data during the
treatment period.
jects 
Q = Fride
m
i
E
m
j
p
a
j
ca Subjects treated during the double-blind study.
b QTc value >450 ms  recorded at only one of the scheduled visits, except for 2 sub
Tc  = QT interval corrected for heart rate; QTcB = Bazett’s correction formula; QTcF 
ost commonly taken concomitant non-AEDs were paracetamol,
buprofen, and lorazepam (used for any indication).
CG evaluations revealed no clinically signiﬁcant results
Pooled data analysis (Table 4) indicated that no subject had a
aximum QTcB or QTcF value >500 ms,  and the percentages of sub-
ects with values >450 ms  were similar between perampanel and
lacebo treatment groups for QTcB (1.3% and 1.4%, respectively)
nd for QTcF (0.8% and 0.5%, respectively). The percentages of sub-
ects with changes from baseline of >60 ms  were low and were
omparable between perampanel and placebo treatment groups
Figure 5. Relationship between perampanel plasma concentration and the(8 mg perampanel) with more than one QTcB value >450 ms.
ricia’s correction formula.
for QTcB (0.2% and 0.2%, respectively) and for QTcF (0.2% and
0.5%, respectively). There was no dose-dependent increase in the
proportion of subjects with either abnormal results or large incre-
mental changes from baseline in QTcB or QTcF. There were more
females with values >450 ms  for QTcB (n = 10 perampanel; n = 4
placebo) or QTcF (n = 6 perampanel; n = 2 placebo) than males [QTcB
(n = 3 perampanel; n = 2 placebo) or QTcF (n = 2 perampanel; n = 0
placebo)]. Concomitant medications known to induce QT  prolonga-
tion (Composite List of Drugs, 2014; Fazio et al., 2013; Letsas et al.,
2011) were taken by 6 subjects with values >450 ms  for QTcB (n = 1
perampanel, n = 3 placebo) or QTcF (n = 2 perampanel).
 QTc interval in pooled Phase III studies. CFB = change from baseline.
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o relationship was observed between plasma perampanel
oncentration and QT interval duration
Regression analysis of individual perampanel concentrations
ersus corresponding QTc intervals in the Phase III studies did not
ndicate a clinically important relationship between plasma peram-
anel concentration and QT interval duration (Fig. 5), with plasma
oncentrations of perampanel ranging from 1.5 to 2519.7 ng/mL.
here is no evidence of prolonged QT interval duration with per-
mpanel treatment over a wide concentration range, higher than
hat observed in healthy subjects in the Phase I thorough QT study.
iscussion
The most common cause of epilepsy-related death is sudden
nexpected death in epilepsy (SUDEP), accounting for 7–17% of
eaths in these patients (Christidis et al., 2006; Feldman and
idal, 2013). Although the pathophysiology of SUDEP has not been
ully elucidated, possible mechanisms include impaired cardiac
epolarization and seizure-associated arrhythmias (Feldman and
idal, 2013). Off-target effects of certain AEDs may  pose a risk for
engthening the QT interval and disrupting cardiac repolarization,
articularly those that work through blocking voltage-gated ion
hannels (Feldman and Gidal, 2013). However, experimental and
linical ﬁndings suggest that AEDs pose little risk of increasing QT
nterval prolongation (Feldman and Gidal, 2013). Furthermore, pro-
ongation of the QT interval has been linked to an increased risk for
ardiac arrhythmias, most commonly TdP, during treatment with
 number of different drugs (ICH Expert Working Group, 2005;
ollard et al., 2008; Redfern et al., 2003). As a result, regulatory
uthorities usually require a thorough QT study during the course
f drug development to assess the potential for drug-induced pro-
ongation of the QT interval.
In this report, we demonstrated that the AED perampanel does
ot appear to affect QT interval duration in either of the study
opulations examined. The results of the Phase I thorough QT
tudy indicate that time-matched, baseline-adjusted mean QTcF
ifferences were comparable between perampanel- and placebo-
reated healthy subjects at both the 6 mg  “mid-therapeutic” and
he 12 mg  “high-therapeutic” doses. In addition, the pooled analy-
is of patients with partial seizures from Phase III studies showed
 weak and clinically unimportant relationship between plasma
erampanel concentration and QT interval duration.
The ICH E14 Guidance states that characterization of the
ose–effect and time course relationships in thorough QT/QTc stud-
es should include “exploration of concentrations that are higher
han those achieved following anticipated therapeutic doses.” Fur-
hermore, the guidance also states that “the drug should be tested
t substantial multiples of the anticipated maximum therapeutic
xposure” (ICH Expert Working Group, 2005). The Phase I thor-
ugh QT study did not include a perampanel dose higher than the
aximum recommended daily dose of 12 mg  (Fycompa Prescribing
nformation, 2014). The rationale for not performing studies of per-
mpanel at doses higher than 12 mg/day is threefold. In studies
f perampanel treatment, the frequency and severity of drug-
elated AEs, dose reductions, and discontinuations at multiple
oses of 12 mg/day have indicated that this dose is at or near the
aximum tolerated dose (MTD) in healthy subjects. Furthermore,
lternate study designs that include the recommended dose titra-
ion schedule for perampanel (initiate treatment at 2 mg/day, with
ose increases no more frequently than weekly at increments of
 mg)  (Fycompa Prescribing Information 2014) were considered
rohibitively impractical to utilize in a thorough QT study due to the
equired length of time needed to obtain target exposures. Finally,
tudies have consistently shown a lack of effect of perampanel
reatment on QT interval duration. This threefold rationale providesch 114 (2015) 122–130 129
support for the adequacy of the Phase I thorough QT study design
with regard to the recommended guidelines. A potential limitation
of the Phase I study is the perampanel exposure at steady state
being substantially higher than after a single dose; thus a 7-day
repeated dosing design was used to achieve the clinically relevant
“Therapeutic” and “Supratherapeutic” exposures without leading
to unnecessarily long exposure of perampanel in healthy subjects.
Furthermore, the dosing regimen was intended to achieve target
plasma concentrations rather than steady state. The purpose of
including expanded ECG assessments in the Phase III studies was
to “bridge” the concentration–QT response determined in healthy
subjects with the concentration–QT response seen in patients with
partial seizures. The pooled analysis of Phase III concentration–QT
response data shows no signiﬁcant effect of perampanel. In addi-
tion to the clinical ﬁndings, nonclinical data including an hERG
assay, cardiovascular safety studies in dogs, and QT/QTc intervals
after repeated dosing for 39 weeks in cynomolgus monkeys did not
reveal any effects of perampanel.
Conclusions
In a Phase I thorough QT study conducted in healthy subjects,
cardiac repolarization and other ECG parameters were not affected
by a 7-day administration of a 6 mg  “mid-therapeutic” or a 12 mg
“high-therapeutic” dose of perampanel. In support of these data, in
a population analysis of patients with partial seizures treated with
up to 12 mg  perampanel in Phase III studies, no clinically impor-
tant trends in QT interval data were noted. A relationship between
plasma perampanel concentration and QT interval duration was
not observed in healthy volunteers or in subjects from the pooled
Phase III double-blind studies. Taken together, the results show
that perampanel (12 mg)  does not prolong the QT interval to any
clinically relevant extent and routine monitoring for cardiac param-
eters is not required for patients taking perampanel as prescribed
(Fycompa Prescribing Information, 2014).
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